Category Archives: Drug prices

 The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?

 Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable.  Advertisements

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment

If Modi Really Wants Affordable Medicines, Why is His Niti Aayog Pushing in the Opposite Direction?

The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog … Continue reading

Posted in Drug prices, Innovation, Uncategorized | Leave a comment

Update from India on Xtandi (Enzalutamide) for cancer treatment

In January 2016, KEI and the Union for Affordable Cancer Treatment petitioned the US the Department of Health and Human Services or the National Institutes of Health to use the federal government rights in the patents on the prostate cancer … Continue reading

Posted in Cancer, Drug prices, Patent, Uncategorized | Tagged , , , | Leave a comment

Pharma Companies Should Sell Medicines Under Generic Names! Generic Prescription by Doctors is NOT Enough

Press Release: April 26, 2017 All India Drug Action Network Demands Substantive Measures   The proposal, as announced by the Prime Minister, to make generic prescription writing mandatory for doctors, would be a useless counterproductive step as a standalone measure. This … Continue reading

Posted in Drug prices, Generics, Uncategorized | Leave a comment

US Bill on drug prices: Improving Access to Affordable Prescription Drugs Act

Source: www.franken.senate.gov A bill on drug prices has been introduced in US Congress to bring down prescription drug prices. The Improving Access to Affordable Prescription Drugs Act aims to ensure that drug companies put patients before profits and bring relief to families … Continue reading

Posted in Drug prices, Innovation, Transparency, Uncategorized | Leave a comment

Compulsory licensing in Colombia: Leaked documents show aggressive lobbying by Novartis

Novartis has threatened Colombia with international investment arbitration to avoid the issuance of a compulsory license.* The Swiss pharma giant is also turning to Colombian courts in an attempt to kill the price reduction imposed by the authorities over its … Continue reading

Posted in BITS, Drug prices, Drugs, ISDS, Pricing | Leave a comment

The high price of Big Pharma greed

By Leena Menghaney, The Hindu | March 4, 2017 In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, … Continue reading

Posted in Biologics/Biosimilars, Drug prices, Uncategorized | Tagged , , | Leave a comment